5 Key Takeaways
-
1
VIS-101, a bispecific inhibitor, improved visual acuity in patients with neovascular age-related macular degeneration (nAMD).
-
2
The therapy showed mean gains of over 10 letters on the ETDRS scale and reduced retinal thickness by 100-150 µm after three doses.
-
3
Approximately two-thirds of patients required no retreatment at 4 months, with about half remaining retreatment-free at 6 months.
-
4
The phase 2a study enrolled 38 patients aged 50 to 80 years, randomized to receive either 6 mg or 3 mg of VIS-101.
-
5
A phase 2b study is planned for 2026, with ongoing investigations of VIS-101 for diabetic macular edema and retinal vein occlusion.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
